Max Flogegård

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

María‐Victoria Mateos, Hareth Nahi, Wojciech Legieć et al. · The Lancet Haematology · 2020 · 241 citations · Full text

Medicine, Oncology, Pharmacology +14

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Bengt Simonsson, Tobias Gedde‐Dahl, Berit Markevärn et al. · Blood · 2011 · 194 citations · Full text

Medicine, Hematology, Oncology +10

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

Saad Z. Usmani, Hareth Nahi, Wojciech Legieć et al. · Haematologica · 2022 · 51 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population

Johan Liwing, Katarina Uttervall, Johan Lund et al. · British Journal of Haematology · 2013 · 48 citations

Medicine, Pharmacology, Pharmacotherapy +13